Disease Burden and Associated Factors in Chinese Patients with Tuberous Sclerosis Complex: Results of a Patient and Caregiver Survey.

Fangping Wang, Luyang Zhang, Jianxiang Liao, Jinzhu Liu, Bixia Yuan, Jinghua Ye
Author Information
  1. Fangping Wang: Department of Neurology, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, People's Republic of China. ORCID
  2. Luyang Zhang: Department of Haematology and Oncology, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, People's Republic of China.
  3. Jianxiang Liao: Department of Neurology, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, People's Republic of China.
  4. Jinzhu Liu: TSC China Alliance, Beijing, People's Republic of China.
  5. Bixia Yuan: TSC China Alliance, Beijing, People's Republic of China.
  6. Jinghua Ye: Department of Neurology, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, People's Republic of China.

Abstract

Objective: Tuberous Sclerosis Complex (TSC) is a rare autosomal dominant genetic disorder primarily characterized by neurological symptoms. This study aimed to evaluate the current disease burden in Chinese patients with TSC and to identify the potential influencing factors.
Methods: A cross-sectional study design was employed using an online questionnaire survey. The questionnaire covered demographics, diagnosis and treatment status, medication use, and disease burden. Descriptive statistics were used to summarize the data, and multivariate logistic regression analysis was performed to examine factors influencing the disease burden in pediatric and adult patients with TSC.
Results: The survey involved a total of 840 patients or their caregivers, comprising 691 pediatric and 149 adult patients, with an average age at diagnosis of 1.77 years for pediatric patients and 15.28 years for adult patients. The most prevalent clinical manifestations were seizures (75.1% in pediatric, 43.6% in adult), brain calcification spots/nodules (87.8% pediatric, 82.5% adult), and hypomelanotic macules (89.5% pediatric, 72.4% adult). Intellectual disability (ID) was reported in 29.6% of pediatric patients and 19.4% of adult patients. Catastrophic health expenditure (CHE) was reported by 29.6% of patients. Factors influencing the disease burden included ID, misdiagnosis, and use of anti-seizure medications (ASMs) and mammalian target of rapamycin (mTOR) inhibitors for pediatric patients or educational attainment, medication use (such as ASMs and mTOR inhibitors), and ID for adult patients.
Conclusion: The study demonstrated that Chinese patients with TSC are confronted with a considerable disease burden. Comprehensive care strategies, tailored educational support for pediatric patients, and multidisciplinary approaches for early diagnosis are crucial for managing TSC.

Keywords

References

  1. Orphanet J Rare Dis. 2017 Jan 5;12(1):2 [PMID: 28057044]
  2. Am J Med Genet A. 2009 Mar;149A(3):387-95 [PMID: 19215038]
  3. Curr Med Res Opin. 2011 Aug;27(8):1571-83 [PMID: 21692602]
  4. JAMA. 2023 May 16;329(19):1682-1692 [PMID: 37191700]
  5. Psychiatr Pol. 2022 May 3;:1-20 [PMID: 36370437]
  6. Lancet Neurol. 2015 Jul;14(7):733-45 [PMID: 26067126]
  7. J Neurodev Disord. 2023 Sep 14;15(1):32 [PMID: 37710171]
  8. J Urol. 1998 Jul;160(1):141-5 [PMID: 9628635]
  9. J Child Neurol. 2015 Oct;30(12):1574-81 [PMID: 25838447]
  10. Med J Aust. 2018 Mar 19;208(5):226-233 [PMID: 29540143]
  11. Pediatr Neurol. 2021 Oct;123:50-66 [PMID: 34399110]
  12. Pediatrics. 2011 Jan;127(1):e117-25 [PMID: 21173003]
  13. Neuropediatrics. 2002 Oct;33(5):255-61 [PMID: 12536368]
  14. Semin Pediatr Neurol. 2021 Apr;37:100875 [PMID: 33892851]
  15. CNS Neurosci Ther. 2021 Mar;27(3):280-288 [PMID: 33225634]
  16. Kidney Int. 2006 Nov;70(10):1777-82 [PMID: 17003820]
  17. Acta Neurol Belg. 2024 Jun;124(3):973-979 [PMID: 38523222]
  18. Handb Clin Neurol. 2013;111:707-18 [PMID: 23622218]
  19. Orphanet J Rare Dis. 2021 Jun 2;16(1):250 [PMID: 34078440]
  20. Orphanet J Rare Dis. 2018 Sep 10;13(1):157 [PMID: 30201051]
  21. Epilepsia. 2021 Jul;62(7):1494-1504 [PMID: 34013535]
  22. Front Public Health. 2023 Jun 08;11:1176170 [PMID: 37361148]
  23. BMJ Open. 2013 Dec 06;3(12):e003707 [PMID: 24319280]
  24. Hosp Pediatr. 2017 Jul;7(7):385-394 [PMID: 28572146]
  25. Orphanet J Rare Dis. 2020 Sep 25;15(1):264 [PMID: 32988393]
  26. Eur J Paediatr Neurol. 2023 Nov;47:25-34 [PMID: 37669572]
  27. Pediatr Dermatol. 2016 Sep;33(5):518-25 [PMID: 27436143]
  28. Am J Med Genet C Semin Med Genet. 2018 Sep;178(3):309-320 [PMID: 30117265]
  29. Epilepsy Behav. 2020 Nov;112:107494 [PMID: 33181900]
  30. Orphanet J Rare Dis. 2019 Apr 30;14(1):91 [PMID: 31039793]
  31. Orv Hetil. 2012 Jul 29;153(30):1185-90 [PMID: 22835635]
  32. Orphanet J Rare Dis. 2020 Jan 21;15(1):23 [PMID: 31964424]
  33. Brain Dev. 2000 Jun;22(4):246-55 [PMID: 10838113]

Word Cloud

Created with Highcharts 10.0.0patientspediatricadultburdendiseaseTSCstudyChineseinfluencingdiagnosisuse6%IDTuberousSclerosisfactorsquestionnairesurveymedicationyears5%4%disabilityreported29FactorsASMsmTORinhibitorseducationalObjective:ComplexrareautosomaldominantgeneticdisorderprimarilycharacterizedneurologicalsymptomsaimedevaluatecurrentidentifypotentialMethods:cross-sectionaldesignemployedusingonlinecovereddemographicstreatmentstatusDescriptivestatisticsusedsummarizedatamultivariatelogisticregressionanalysisperformedexamineResults:involvedtotal840caregiverscomprising691149averageage1771528prevalentclinicalmanifestationsseizures751%43braincalcificationspots/nodules878%82hypomelanoticmacules8972Intellectual19CatastrophichealthexpenditureCHEincludedmisdiagnosisanti-seizuremedicationsmammaliantargetrapamycinattainmentConclusion:demonstratedconfrontedconsiderableComprehensivecarestrategiestailoredsupportmultidisciplinaryapproachesearlycrucialmanagingDiseaseBurdenAssociatedPatientsComplex:ResultsPatientCaregiverSurveyChinacostillnesseconomicintellectualmedicalexpensesqualitylifetuberoussclerosiscomplex

Similar Articles

Cited By

No available data.